PALI
NASDAQ · Biotechnology
Palisade Bio Inc
$2.02
+0.05 (+2.54%)
Open$1.99
Previous Close$1.97
Day High$2.05
Day Low$1.96
52W High$2.86
52W Low$0.53
Volume—
Avg Volume6.05M
Market Cap364.52M
P/E Ratio—
EPS$-1.17
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+117.8% upside
Current
$2.02
$2.02
Target
$4.40
$4.40
$2.36
$4.40 avg
$4.89
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 116.39M | 123.33M | 94.21M |
| Net Income | 12.19M | 12.43M | 9.10M |
| Profit Margin | 10.5% | 10.1% | 9.7% |
| EBITDA | 16.58M | 20.40M | 14.08M |
| Free Cash Flow | 11.50M | 12.12M | 8.26M |
| Rev Growth | -3.2% | +20.3% | +7.0% |
| Debt/Equity | 0.59 | 0.58 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $261.07 | +3.99% | 126.9 | 461.26B |
| AMGN | Amgen Inc | $374.15 | +3.55% | 25.9 | 201.93B |
| GILD | Gilead Sciences Inc | $131.27 | +4.21% | 17.7 | 162.98B |
| VRTX | Vertex Pharmaceuticals Inc | $528.04 | +6.03% | 30.4 | 131.79B |
| REGN | Regeneron Pharmaceuticals | $654.27 | +4.73% | 15.5 | 68.59B |
| ALNY | Alnylam Pharmaceuticals Inc | $312.78 | +3.68% | 72.4 | 41.76B |